NicOx
 |
 | |
| Company type | Société Anonyme |
|---|---|
| Euronext: COX | |
| Industry | research and development in biotechnology  |
| Founded | 1996 |
| Headquarters | , |
| Website | www |
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.[1] Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.[2][3]
Nicox is listed on Euronext Paris[4] (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.[5]
Pipeline
[edit]Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma.[6] NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.[7][8]
The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.[9] Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Eyevance Pharmaceuticals and Ocumension Therapeutics.[10][11]
Agreement with Ocumension
[edit]In 2019, Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a cetirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligible for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of future development and regulatory milestones.[12]
References
[edit]- ^ "COX: Nicox Stock Price Quote - EN Paris - Bloomberg". Bloomberg News.
- ^ "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.
- ^ "Michele Garufi, PDG de NicOx".
- ^ "| live".
- ^ "Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".
- ^ Clinical trial number NCT03657797 for "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" at ClinicalTrials.gov
- ^ Sambhara, Deepak; Aref, Ahmad A. (2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease. 5 (1): 30–43. doi:10.1177/2040622313511286. PMC 3871276. PMID 24381726.
- ^ "Prostaglandin analogs: The "gold standard" for glaucoma".
- ^ Clinical trial number NCT03926026 for "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis" at ClinicalTrials.gov
- ^ "NICOX: Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States". Bloomberg.com. 31 March 2020.
- ^ "BRIEF-Nicox Updates Agreement with Ocumension Therapeutics on ZERVIATE". Reuters. 11 March 2020. Archived from the original on June 11, 2020.
- ^ NICOX (2021-07-05). "Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement". GlobeNewswire News Room. Retrieved 2021-09-19.